Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Influenza

  Free Subscription


20.06.2022

7 Antiviral Res
5 BMJ
3 Cell
1 Drug Saf
1 Epidemiol Infect
3 J Epidemiol Community Health
1 J Immunol
23 J Infect
2 J Virol
1 JAMA
5 Lancet
1 Minerva Pediatr (Torino)
2 MMWR Morb Mortal Wkly Rep
6 N Engl J Med
1 PLoS Biol
1 PLoS Comput Biol
3 PLoS Med
34 PLoS One
6 Proc Natl Acad Sci U S A
7 Vaccine


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Antiviral Res

  1. PRASHAR P, Swain S, Adhikari N, Aryan P, et al
    A novel high-throughput single B-cell cloning platform for isolation and characterization of high-affinity and potent SARS-CoV-2 neutralizing antibodies.
    Antiviral Res. 2022 May 28:105349. doi: 10.1016/j.antiviral.2022.105349.
    PubMed         Abstract available

  2. LIN Q, Lu C, Hong Y, Li R, et al
    Animal models for studying coronavirus infections and developing antiviral agents and vaccines.
    Antiviral Res. 2022 May 20:105345. doi: 10.1016/j.antiviral.2022.105345.
    PubMed         Abstract available

  3. ROY A, Alhammad YM, McDonald P, Johnson DK, et al
    Discovery of compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding by high-throughput screening.
    Antiviral Res. 2022 May 19:105344. doi: 10.1016/j.antiviral.2022.105344.
    PubMed         Abstract available

  4. WEIL T, Lawrenz J, Seidel A, Munch J, et al
    Immunodetection assays for the quantification of seasonal common cold coronaviruses OC43, NL63, or 229E infection confirm nirmatrelvir as broad coronavirus inhibitor.
    Antiviral Res. 2022 May 19:105343. doi: 10.1016/j.antiviral.2022.105343.
    PubMed         Abstract available

  5. VANHULLE E, Stroobants J, Provinciael B, Camps A, et al
    SARS-CoV-2 Permissive glioblastoma cell line for high throughput antiviral screening.
    Antiviral Res. 2022 May 17:105342. doi: 10.1016/j.antiviral.2022.105342.
    PubMed         Abstract available

  6. FINDLAY-WILSON S, Easterbrook L, Smith S, Pope N, et al
    Development of a cost-effective ovine antibody-based therapy against SARS-CoV-2 infection and contribution of antibodies specific to the spike subunit proteins.
    Antiviral Res. 2022 May 6:105332. doi: 10.1016/j.antiviral.2022.105332.
    PubMed         Abstract available

  7. PITTS J, Babusis D, Vermillion MS, Subramanian R, et al
    Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infection.
    Antiviral Res. 2022 May 4:105329. doi: 10.1016/j.antiviral.2022.105329.
    PubMed         Abstract available


    BMJ

  8. WISE J
    Covid-19: Patients without respiratory symptoms no longer have to wear a face mask in GP surgeries.
    BMJ. 2022;377:o1445.
    PubMed        

  9. HITCHINGS MDT, Ranzani OT, Lind ML, Dorion M, et al
    Change in covid-19 risk over time following vaccination with CoronaVac: test negative case-control study.
    BMJ. 2022;377:e070102.
    PubMed         Abstract available

  10. DYER C
    Covid-19: Unusable PPE worth pound4bn will be burned, says spending watchdog.
    BMJ. 2022;377:o1435.
    PubMed        

  11. MAZZILLI S, Moazen B, Stover H, Plugge E, et al
    Covid-19 vaccine in prison: a not-to-be-missed opportunity to promote access to vaccination in adolescents.
    BMJ. 2022;377:o1439.
    PubMed        

  12. PANDEY BD, Morita K, Costello A
    Twin crises in Nepal: covid-19 and climate change.
    BMJ. 2022;377:o1434.
    PubMed        


    Cell

  13. NUTALAI R, Zhou D, Tuekprakhon A, Ginn HM, et al
    Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
    Cell. 2022;185:2116-2131.
    PubMed         Abstract available

  14. YAMASOBA D, Kimura I, Nasser H, Morioka Y, et al
    Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike.
    Cell. 2022;185:2103-2115.
    PubMed         Abstract available

  15. CHATURVEDI S, Pablo M, Wolf M, Rosas-Rivera D, et al
    Disrupting autorepression circuitry generates "open-loop lethality" to yield escape-resistant antiviral agents.
    Cell. 2022;185:2086-2102.
    PubMed         Abstract available


    Drug Saf

  16. SHOAIBI A, Rao GA, Voss EA, Ostropolets A, et al
    Phenotype Algorithms for the Identification and Characterization of Vaccine-Induced Thrombotic Thrombocytopenia in Real World Data: A Multinational Network Cohort Study.
    Drug Saf. 2022;45:685-698.
    PubMed         Abstract available


    Epidemiol Infect

  17. ZHAO X, Shen Z, Sun L, Cheng L, et al
    A network meta-analysis of secondary attack rates of COVID-19 in different contact environments.
    Epidemiol Infect. 2021;149:e219.
    PubMed         Abstract available


    J Epidemiol Community Health

  18. MATZ M, Allemani C, van Tongeren M, Nafilyan V, et al
    Excess mortality among essential workers in England and Wales during the COVID-19 pandemic.
    J Epidemiol Community Health. 2022;76:660-666.
    PubMed         Abstract available

  19. DOLBY T, Finning K, Baker A, Fowler-Dowd L, et al
    Monitoring sociodemographic inequality in COVID-19 vaccination uptake in England: a national linked data study.
    J Epidemiol Community Health. 2022;76:646-652.
    PubMed         Abstract available

  20. SCHULTES O, Lind ML, Brockmeyer J, Sosensky P, et al
    Closing the health inequity gap during the pandemic: COVID-19 mortality among racial and ethnic groups in Connecticut, March 2020 to December 2021.
    J Epidemiol Community Health. 2022;76:695-696.
    PubMed        


    J Immunol

  21. NAGASHIMA K, Dzimianski JV, Han J, Abbadi N, et al
    The Pre-Existing Human Antibody Repertoire to Computationally Optimized Influenza H1 Hemagglutinin Vaccines.
    J Immunol. 2022 Jun 13. pii: jimmunol.2101171. doi: 10.4049/jimmunol.2101171.
    PubMed         Abstract available


    J Infect

  22. SA R, Isidro J, Borges V, Duarte S, et al
    Unravelling the hurdles of a large COVID-19 epidemiological investigation by viral genomics.
    J Infect. 2022 May 21. pii: S0163-4453(22)00302.
    PubMed         Abstract available

  23. SOVIK S, Barrat-Due A, Kasine T, Olasveengen T, et al
    Corticosteroids and superinfections in COVID-19 patients on invasive mechanical ventilation.
    J Infect. 2022 May 20. pii: S0163-4453(22)00305.
    PubMed         Abstract available

  24. WU X, Peng H, Xiong S, Li C, et al
    Novel evidence revealed genetic association between COVID-19 infection, severity and endometrial cancer: COVID-19 infection, severity and risk of endometrial cancer.
    J Infect. 2022 May 10. pii: S0163-4453(22)00261.
    PubMed        

  25. LUO Q, Li M, Li A, Gong C, et al
    Genetic diversity and epidemiological features of respiratory syncytial virus, Beijing, 2015-2019: A multicenter and all-age groups study.
    J Infect. 2022;85:75-85.
    PubMed         Abstract available

  26. WAN Z, Lu R, Zhao Y, Zhang C, et al
    Diagnostic strategy of SARS-CoV-2 for containment under China's zero-COVID-19 policy.
    J Infect. 2022 May 1. pii: S0163-4453(22)00250.
    PubMed        

  27. JIMENEZ D, Martinez-Sanz J, Sainz T, Calvo C, et al
    Differences in saliva ACE2 activity among infected and non-infected adult and pediatric population exposed to SARS-CoV-2.
    J Infect. 2022 Apr 28. pii: S0163-4453(22)00248.
    PubMed         Abstract available

  28. HE L, Zeng C, Xu W, Li Y, et al
    Dynamic changes of serum SARS-CoV-2 antibody levels in COVID-19 patients.
    J Infect. 2022 Apr 21. pii: S0163-4453(22)00214.
    PubMed        

  29. AO G, Li A, Wang Y, Tran C, et al
    Lack of efficacy for sotrovimab use in patients with COVID-19: A meta-analysis.
    J Infect. 2022 Apr 21. pii: S0163-4453(22)00210.
    PubMed        

  30. CIUFFREDA L, Alcoba-Florez J, Lorenzo-Salazar JM, Gil-Campesino H, et al
    Association of the Delta SARS-CoV-2 variant with 28-day hospital mortality between December 2020 and September 2021.
    J Infect. 2022 Apr 21. pii: S0163-4453(22)00212.
    PubMed        

  31. PANDIT P, Bhatt P, Sahay RR, Joshi Y, et al
    A case of breakthrough infection with SARS-CoV-2 Delta derivative and reinfection with Omicron variant in a fully vaccinated health care professional.
    J Infect. 2022 Apr 18. pii: S0163-4453(22)00205.
    PubMed        

  32. CAI J, Hu S, Lin Q, Ren T, et al
    China's 'dynamic zero COVID-19 strategy' will face greater challenges in the future.
    J Infect. 2022 Apr 18. pii: S0163-4453(22)00209.
    PubMed        

  33. DAVIES J, Gibani MM, Portone G, McGregor A, et al
    Cohorting inpatients with Omicron and Delta variants of Sars-CoV-2 does not increase rates of mixed infection.
    J Infect. 2022 Apr 12. pii: S0163-4453(22)00202.
    PubMed        

  34. REN Y, Lv L, Li P, Zhang L, et al
    Inhibition of endocytic recycling of ACE2 by SARS-CoV-2 S protein partially explains multiple COVID-19 related diseases caused by ACE2 reduction.
    J Infect. 2022 Apr 11. pii: S0163-4453(22)00201.
    PubMed        

  35. ZSIGMOND B, Breathnach AS, Mensah A, Ladhani SN, et al
    Very low rates of severe COVID-19 in children hospitalised with confirmed SARS-CoV-2 infection in London, England".
    J Infect. 2022 Apr 10. pii: S0163-4453(22)00203.
    PubMed        

  36. YUAN W, Hou Y, Lin Q, Chen L, et al
    How China responds to Omicron.
    J Infect. 2022;85:90-122.
    PubMed        

  37. YADAV PD, Sahay RR, Agrawal S, Shete A, et al
    Clinical, immunological and genomic analysis of the post vaccinated SARS-CoV-2 infected cases with Delta derivatives from Maharashtra, India, 2021.
    J Infect. 2022 Apr 7. pii: S0163-4453(22)00193.
    PubMed        

  38. LIU Y, Li P, Yang L, Li P, et al
    High vaccination coverage slows down genetic diversity of SARS-CoV-2.
    J Infect. 2022 Apr 7. pii: S0163-4453(22)00191.
    PubMed        

  39. AKBAR S, Pan D, Ehdode A, Islam R, et al
    Prognostic value of maximum NEWS-2 scores in addition to ISARIC 4C scores for patients admitted to hospital with COVID-19.
    J Infect. 2022 Apr 7. pii: S0163-4453(22)00195.
    PubMed        

  40. ONG JY, Wang CH, Ms YT, Chen FL, et al
    Nosocomial septicemia in COVID-19 Nosocomial K. pneumoniae, A. baumannii, and Elizabethkingia meningoseptica Septicemia in a Patient of COVID-19.
    J Infect. 2022 Apr 5. pii: S0163-4453(22)00188.
    PubMed        

  41. SONG W, Yang Y, Huang Y, Chen L, et al
    Acute respiratory infections in children, before and after the COVID-19 pandemic, a sentinel study.
    J Infect. 2022 Apr 5. pii: S0163-4453(22)00183.
    PubMed        

  42. GAGNAIRE J, Bonjean P, Verot E, Boulamail B, et al
    SARS-CoV-2 rapid test versus RT-qPCR on noninvasive respiratory self-samples during a city mass testing campaign.
    J Infect. 2022 Apr 5. pii: S0163-4453(22)00184.
    PubMed        

  43. BAEK YJ, Lee YJ, Kim JI, Lee S, et al
    Prolonged viral shedding in severely ill patients infected with SARS-CoV-2 Delta variants: a retrospective cohort study.
    J Infect. 2022 Apr 5. pii: S0163-4453(22)00186.
    PubMed        

  44. DUVERGER C, Monteil C, Souyri V, Md SF, et al
    Decrease of carbapenemase-producing Enterobacteriaceae incidence during the first year of the COVID-19 pandemic.
    J Infect. 2022 Apr 1. pii: S0163-4453(22)00179.
    PubMed        


    J Virol

  45. CHRISTENSEN SR, Martin ET, Petrie JG, Monto AS, et al
    The 2009 Pandemic H1N1 Hemagglutinin Stalk Remained Antigenically Stable after Circulating in Humans for a Decade.
    J Virol. 2022;96:e0220021.
    PubMed         Abstract available

  46. NCHIOUA R, Schundner A, Kmiec D, Prelli Bozzo C, et al
    SARS-CoV-2 Variants of Concern Hijack IFITM2 for Efficient Replication in Human Lung Cells.
    J Virol. 2022 May 11:e0059422. doi: 10.1128/jvi.00594.
    PubMed         Abstract available


    JAMA

  47. VIJAY A, Yancy CW
    Resident Physician Wellness Postpandemic: How Does Healing Occur?
    JAMA. 2022;327:2077-2078.
    PubMed        


    Lancet

  48. LI G, Cappuccini F, Marchevsky NG, Aley PK, et al
    Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
    Lancet. 2022;399:2212-2225.
    PubMed         Abstract available

  49. WONG HL, Hu M, Zhou CK, Lloyd PC, et al
    Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases.
    Lancet. 2022;399:2191-2199.
    PubMed         Abstract available

  50. PATEL M, Patel M
    Increasing children's global access to COVID-19 vaccines.
    Lancet. 2022;399:2171-2173.
    PubMed        

  51. HUSBY A, Kober L
    COVID-19 mRNA vaccination and myocarditis or pericarditis.
    Lancet. 2022;399:2168-2169.
    PubMed        

  52. CHRISTENSON SA, Smith BM, Bafadhel M, Putcha N, et al
    Chronic obstructive pulmonary disease.
    Lancet. 2022 May 6. pii: S0140-6736(22)00470.
    PubMed         Abstract available


    Minerva Pediatr (Torino)

  53. MORMILE R
    Apnea induced by respiratory syncytial virus infection: an inappropriate immune response requiring long-term follow-up for adult-onset progressive neurodegenerative diseases?
    Minerva Pediatr (Torino). 2022;74:374-375.
    PubMed        


    MMWR Morb Mortal Wkly Rep

  54. PAMPATI S, Rasberry CN, McConnell L, Timpe Z, et al
    Ventilation Improvement Strategies Among K-12 Public Schools - The National School COVID-19 Prevention Study, United States, February 14-March 27, 2022.
    MMWR Morb Mortal Wkly Rep. 2022;71:770-775.
    PubMed         Abstract available

  55. KRISS JL, Hung MC, Srivastav A, Black CL, et al
    COVID-19 Vaccination Coverage, by Race and Ethnicity - National Immunization Survey Adult COVID Module, United States, December 2020-November 2021.
    MMWR Morb Mortal Wkly Rep. 2022;71:757-763.
    PubMed         Abstract available


    N Engl J Med

  56. LEUCHTER RK, Jackson NJ, Mafi JN, Sarkisian CA, et al
    Association between Covid-19 Vaccination and Influenza Vaccination Rates.
    N Engl J Med. 2022 Jun 15. doi: 10.1056/NEJMc2204560.
    PubMed        

  57. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Protecting the Immunocompromised from Covid-19.
    N Engl J Med. 2022;386:e71.
    PubMed        

  58. ABRAHAM J
    Monoclonal Antibodies with Extended Half-Life to Prevent Covid-19.
    N Engl J Med. 2022;386:2236-2238.
    PubMed        

  59. GOLDBERG Y, Mandel M, Bar-On YM, Bodenheimer O, et al
    Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2.
    N Engl J Med. 2022 May 25. doi: 10.1056/NEJMoa2118946.
    PubMed         Abstract available

  60. GRAY G, Collie S, Goga A, Garrett N, et al
    Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa.
    N Engl J Med. 2022 May 4. doi: 10.1056/NEJMc2202061.
    PubMed        

  61. LEVIN MJ, Ustianowski A, De Wit S, Launay O, et al
    Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.
    N Engl J Med. 2022 Apr 20. doi: 10.1056/NEJMoa2116620.
    PubMed         Abstract available


    PLoS Biol

  62. GRIFFIN DE
    Why does viral RNA sometimes persist after recovery from acute infections?
    PLoS Biol. 2022;20:e3001687.
    PubMed         Abstract available


    PLoS Comput Biol

  63. LENG T, Hill EM, Thompson RN, Tildesley MJ, et al
    Assessing the impact of lateral flow testing strategies on within-school SARS-CoV-2 transmission and absences: A modelling study.
    PLoS Comput Biol. 2022;18:e1010158.
    PubMed         Abstract available


    PLoS Med

  64. MARTIN CA, Pan D, Melbourne C, Teece L, et al
    Risk factors associated with SARS-CoV-2 infection in a multiethnic cohort of United Kingdom healthcare workers (UK-REACH): A cross-sectional analysis.
    PLoS Med. 2022;19:e1004015.
    PubMed         Abstract available

  65. BRUMMER LE, Katzenschlager S, McGrath S, Schmitz S, et al
    Accuracy of rapid point-of-care antigen-based diagnostics for SARS-CoV-2: An updated systematic review and meta-analysis with meta-regression analyzing influencing factors.
    PLoS Med. 2022;19:e1004011.
    PubMed         Abstract available

  66. JIN P, Guo X, Chen W, Ma S, et al
    Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.
    PLoS Med. 2022;19:e1003953.
    PubMed         Abstract available


    PLoS One

  67. BOHN-GOLDBAUM E, Owen KB, Lee VYJ, Booy R, et al
    Physical activity and acute exercise benefit influenza vaccination response: A systematic review with individual participant data meta-analysis.
    PLoS One. 2022;17:e0268625.
    PubMed         Abstract available

  68. ROY S, Iktidar MA, Chowdhury S, Islam AMK, et al
    Prevalence of dermatological manifestations due to face mask use and its associated factors during COVID-19 among the general population of Bangladesh: A nationwide cross-sectional survey.
    PLoS One. 2022;17:e0269922.
    PubMed         Abstract available

  69. TORRES ML, Palma Diaz D, Oliver-Parra A, Millet JP, et al
    Inequities in the incidence and mortality due to COVID-19 in nursing homes in Barcelona by characteristics of the nursing homes.
    PLoS One. 2022;17:e0269639.
    PubMed         Abstract available

  70. PAPANEOPHYTOU C, Nicolaou A, Pieri M, Nicolaidou V, et al
    Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus.
    PLoS One. 2022;17:e0269885.
    PubMed         Abstract available

  71. CAPPS O JR
    Dynamics of macroeconomic factor effects on food assistance program participation in the United States.
    PLoS One. 2022;17:e0269442.
    PubMed         Abstract available

  72. MINKUS L, Groepler N, Drobnic S
    The significance of occupations, family responsibilities, and gender for working from home: Lessons from COVID-19.
    PLoS One. 2022;17:e0266393.
    PubMed         Abstract available

  73. UCHIDA M, Yamauchi T
    Rate of diagnosed seasonal influenza in children with influenza-like illness: A cross-sectional study.
    PLoS One. 2022;17:e0269804.
    PubMed         Abstract available

  74. RANGELOVA V, Raycheva R, Sariyan S, Kevorkyan A, et al
    Reporting adverse events of COVID-19 vaccines: The case of Bulgaria.
    PLoS One. 2022;17:e0269727.
    PubMed         Abstract available

  75. HOLDSWORTH DA, Chamley R, Barker-Davies R, O'Sullivan O, et al
    Comprehensive clinical assessment identifies specific neurocognitive deficits in working-age patients with long-COVID.
    PLoS One. 2022;17:e0267392.
    PubMed         Abstract available

  76. GANZ T, Sanderson S, Baush C, Mejia M, et al
    Performance of the TaqMan COVID-19 Pooling Kit for detection of SARS-CoV-2 in asymptomatic and symptomatic populations.
    PLoS One. 2022;17:e0269798.
    PubMed         Abstract available

  77. HANGARTNER N, Di Gangi S, Elbl C, Senn O, et al
    Impact of the COVID-19 pandemic on emergency outpatient consultations and admissions of non-COVID-19 patients (ECCO)-A cross-sectional study.
    PLoS One. 2022;17:e0269724.
    PubMed         Abstract available

  78. MARTIGNONI MM, Renault J, Baafi J, Hurford A, et al
    Downsizing of COVID-19 contact tracing in highly immune populations.
    PLoS One. 2022;17:e0268586.
    PubMed         Abstract available

  79. KOBASHI Y, Shimazu Y, Kawamura T, Nishikawa Y, et al
    Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine.
    PLoS One. 2022;17:e0269917.
    PubMed         Abstract available

  80. CASEMIRO LKDDS, Lopes-Junior LC, Jardim FA, Sulino MC, et al
    Telehealth in outpatient care for children and adolescents with chronic conditions during the COVID-19 pandemic: A scoping review protocol.
    PLoS One. 2022;17:e0269821.
    PubMed         Abstract available

  81. KANGRO K, Kurasin M, Gildemann K, Sankovski E, et al
    Bovine colostrum-derived antibodies against SARS-CoV-2 show great potential to serve as prophylactic agents.
    PLoS One. 2022;17:e0268806.
    PubMed         Abstract available

  82. MASYENI S, Nelwan EJ, Fatawy RM, Wibawa S, et al
    Clinical characteristics and outcomes of COVID-19 patients in Bali, Indonesia.
    PLoS One. 2022;17:e0269026.
    PubMed         Abstract available

  83. BRACEGIRDLE L, Jackson A, Beecham R, Burova M, et al
    Dynamic blood oxygen indices in mechanically ventilated COVID-19 patients with acute hypoxic respiratory failure: A cohort study.
    PLoS One. 2022;17:e0269471.
    PubMed         Abstract available

  84. JOSHI A, Surapaneni KM, Kaur M, Bhatt A, et al
    A cross sectional study to examine factors influencing COVID-19 vaccine acceptance, hesitancy and refusal in urban and rural settings in Tamil Nadu, India.
    PLoS One. 2022;17:e0269299.
    PubMed         Abstract available

  85. YIGEZU A, Zewdie SA, Mirkuzie AH, Abera A, et al
    Cost-analysis of COVID-19 sample collection, diagnosis, and contact tracing in low resource setting: The case of Addis Ababa, Ethiopia.
    PLoS One. 2022;17:e0269458.
    PubMed         Abstract available

  86. SAVIN I, Drews S, van den Bergh J, Villamayor-Tomas S, et al
    Public expectations about the impact of COVID-19 on climate action by citizens and government.
    PLoS One. 2022;17:e0266979.
    PubMed         Abstract available

  87. PRENTISS M, Chu A, Berggren KK
    Finding the infectious dose for COVID-19 by applying an airborne-transmission model to superspreader events.
    PLoS One. 2022;17:e0265816.
    PubMed         Abstract available

  88. WALENDY V, Girndt M, Greinert D
    COVID-19 and acute kidney injury in German hospitals 2020.
    PLoS One. 2022;17:e0264510.
    PubMed         Abstract available

  89. SARAF S, Zhu X, Shrestha R, Bonny TS, et al
    Differential antibody production by symptomatology in SARS-CoV-2 convalescent individuals.
    PLoS One. 2022;17:e0264298.
    PubMed         Abstract available

  90. BOHLIN J, Page CM, Lee Y, Pettersson JH, et al
    Age and sex effects on DNA methylation sites linked to genes implicated in severe COVID-19 and SARS-CoV-2 host cell entry.
    PLoS One. 2022;17:e0269105.
    PubMed         Abstract available

  91. AMORE M, Garofalo O, Martin-Sanchez V
    Dispositional optimism and business recovery during a pandemic.
    PLoS One. 2022;17:e0269707.
    PubMed         Abstract available

  92. KHAIRKHAH N, Bolhassani A, Agi E, Namvar A, et al
    Immunological investigation of a multiepitope peptide vaccine candidate based on main proteins of SARS-CoV-2 pathogen.
    PLoS One. 2022;17:e0268251.
    PubMed         Abstract available

  93. TSORI Y, Granek R
    Spatio-temporal spread of COVID-19: Comparison of the inhomogeneous SEPIR model and data from South Carolina.
    PLoS One. 2022;17:e0268995.
    PubMed         Abstract available

  94. BONNICI V, Cicceri G, Distefano S, Galletta L, et al
    Covid19/IT the digital side of Covid19: A picture from Italy with clustering and taxonomy.
    PLoS One. 2022;17:e0269687.
    PubMed         Abstract available

  95. BITZENHOFER M, Suter-Riniker F, Moor MB, Sidler D, et al
    Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease.
    PLoS One. 2022;17:e0268780.
    PubMed         Abstract available

  96. KORLAT S, Holzer J, Reiter J, Pelikan ER, et al
    The role of the Big Two in socially responsible behavior during the COVID-19 pandemic: Agency and communion in adolescents' personal norm and behavioral adherence to instituted measures.
    PLoS One. 2022;17:e0269018.
    PubMed         Abstract available

  97. PAWLOS A, Gorzelak-Pabis P, Staciwa M, Broncel M, et al
    Elevated Lp(a) and course of COVID-19: Is there a relationship?
    PLoS One. 2022;17:e0266814.
    PubMed         Abstract available

  98. NECESITO IV, Velasco JMS, Jung J, Bae YH, et al
    Understanding chaos in COVID-19 and its relationship to stringency index: Applications to large-scale and granular level prediction models.
    PLoS One. 2022;17:e0268023.
    PubMed         Abstract available

  99. FRAENKL M, Krbal M, Houdek J, Zmrhalova ZO, et al
    High-quality and easy-to-regenerate personal filter.
    PLoS One. 2022;17:e0268542.
    PubMed         Abstract available

  100. SLYKERMAN RF, Li E, Mitchell EA
    Probiotics for Reduction of Examination Stress in Students (PRESS) study: A randomized, double-blind, placebo-controlled trial of the probiotic Lacticaseibacillus rhamnosus HN001.
    PLoS One. 2022;17:e0267778.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  101. ANAHTAR M, Chan LW, Ko H, Rao A, et al
    Host protease activity classifies pneumonia etiology.
    Proc Natl Acad Sci U S A. 2022;119:e2121778119.
    PubMed         Abstract available

  102. GALVANI AP, Parpia AS, Pandey A, Sah P, et al
    Universal healthcare as pandemic preparedness: The lives and costs that could have been saved during the COVID-19 pandemic.
    Proc Natl Acad Sci U S A. 2022;119:e2200536119.
    PubMed         Abstract available

  103. SIMONETTI B, Daly JL, Simon-Gracia L, Klein K, et al
    ESCPE-1 mediates retrograde endosomal sorting of the SARS-CoV-2 host factor Neuropilin-1.
    Proc Natl Acad Sci U S A. 2022;119:e2201980119.
    PubMed         Abstract available

  104. ALETA A, Martin-Corral D, Bakker MA, Pastore Y Piontti A, et al
    Quantifying the importance and location of SARS-CoV-2 transmission events in large metropolitan areas.
    Proc Natl Acad Sci U S A. 2022;119:e2112182119.
    PubMed         Abstract available

  105. AMERICO JL, Cotter CA, Earl PL, Liu R, et al
    Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.
    Proc Natl Acad Sci U S A. 2022;119:e2202069119.
    PubMed         Abstract available

  106. ENGELBERT BAIN L, Berner-Rodoreda A, McMahon SA, Sarker M, et al
    One lesson of COVID-19: Conduct more health policy trials.
    Proc Natl Acad Sci U S A. 2022;119:e2119887119.
    PubMed        


    Vaccine

  107. KUNASEKARAN MP, Chughtai AA, Heslop DJ, Poulos CJ, et al
    Influenza cases in nine aged care facilities in Sydney, Australia over a three-year surveillance period, 2018-2020.
    Vaccine. 2022 Jun 9. pii: S0264-410X(22)00476.
    PubMed         Abstract available

  108. HALME J, Syrjanen RK, Baum U, Palmu AA, et al
    Effectiveness of trivalent influenza vaccines against hospitalizations due to laboratory-confirmed influenza a in the elderly: Comparison of test-negative design with register-based designs.
    Vaccine. 2022 Jun 9. pii: S0264-410X(22)00716.
    PubMed         Abstract available

  109. FLYNN JA, Weber T, Cejas PJ, Cox KS, et al
    Characterization of humoral and cell-mediated immunity induced by mRNA vaccines expressing influenza hemagglutinin stem and nucleoprotein in mice and nonhuman primates.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00382.
    PubMed         Abstract available

  110. SZANYI J, Wilson T, Scott N, Blakely T, et al
    A log-odds system for waning and boosting of COVID-19 vaccine effectiveness.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00634.
    PubMed         Abstract available

  111. CHONG-VALBUENA A, De-Jesus-Maria I, Agurto-Ramirez A, Puchades-Gimeno F, et al
    Safety of Pfizer-BioNTech vaccine in a cohort of healthcare providers: Differences between naive and previously infected by SARS-CoV-2.
    Vaccine. 2022 May 12. pii: S0264-410X(22)00586.
    PubMed         Abstract available

  112. REES F, Geiger M, Lilleholt L, Zettler I, et al
    Measuring parents' readiness to vaccinate themselves and their children against COVID-19.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00549.
    PubMed         Abstract available

  113. SIQUEIRA PG, Duarte HO, Moura MDC
    Risk-based cost-benefit analysis of alternative vaccines against COVID-19 in Brazil: Coronavac vs. Astrazeneca vs. Pfizer.
    Vaccine. 2022 May 19. pii: S0264-410X(22)00633.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Influenza is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: